Unicycive Therapeutics Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress

Reuters

昨天

Unicycive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress

Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on May 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532863248"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532863248\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532863248?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532863248","market":"us","top_or_hot":-1,"title":"Unicycive Therapeutics Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive Therapeutics Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive Therapeutics Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-02 01:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL1jXNQs:1","article_id":"2532863248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532863248","pubTimestamp":1746121714,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate , aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application  for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","UNCY":"Unicycive Therapeutics, Inc."},"translate_title":"Unicycive Therapeutics Inc.介绍肾脏疾病治疗的新进展，重点介绍OLC和UN-494进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNCY":0.9},"content_text":"Unicycive Therapeutics Inc. Presents New Developments in Kidney Disease Treatments, Highlighting OLC and UN-494 Progress\n    \n\n        Unicycive Therapeutics Inc., listed on NASDAQ under the ticker UNCY, presented its May 2025 corporate presentation highlighting its focus on kidney disease treatments. The company's diversified portfolio includes its lead asset, Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC is currently under review, with a PDUFA date set for June 28, 2025. Unicycive is also developing UN-494 for acute kidney injury and chronic kidney disease. The presentation outlines strategies for OLC's market launch, emphasizing awareness, market shaping, reimbursement facilitation, and commercial operations. It notes a significant market opportunity in hyperphosphatemia, valued at over $1 billion in the US. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}